---
title: "TriSalus Life Sciences - CW | 8-K: FY2026 Q1 Revenue: USD 8.899 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286148597.md"
datetime: "2026-05-12T20:05:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286148597.md)
  - [en](https://longbridge.com/en/news/286148597.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286148597.md)
generator: "portal-rs"
---

# TriSalus Life Sciences - CW | 8-K: FY2026 Q1 Revenue: USD 8.899 M

Revenue: As of FY2026 Q1, the actual value is USD 8.899 M.

EPS: As of FY2026 Q1, the actual value is USD 0.03.

EBIT: As of FY2026 Q1, the actual value is USD -7.139 M.

### Financial and Operational Metrics for Q1 2026

#### Gross Profit and Margin

TriSalus Life Sciences reported a gross profit of $7.669 million for the three months ended March 31, 2026, which was a slight decrease from $7.672 million in the same period of 2025. The gross margin improved to 86.2% in Q1 2026, up from 83.7% in Q1 2025, primarily due to a lower average cost per TriNav unit.

#### Operating Expenses

Research and development expenses increased to $3.216 million in Q1 2026, compared to $3.021 million in Q1 2025. Sales and marketing expenses rose to $7.413 million in Q1 2026 from $6.734 million in Q1 2025, driven by commercial expansion. General and administrative expenses also increased to $5.451 million in Q1 2026 from $5.246 million in Q1 2025.

#### Operating Loss

Loss from operations for Q1 2026 was - $8.411 million, an increase in loss compared to - $7.329 million for the same period in 2025. This increase was mainly due to higher sales and marketing expenses and increased non-cash stock-based compensation, partially offset by improved gross margins.

#### Net Income (Loss) Attributable to Common Stockholders

Net income attributable to common stockholders was $1.539 million for Q1 2026, a significant improvement from a net loss of - $11.087 million in Q1 2025. This change was primarily due to $11.3 million in non-cash gains related to changes in the fair value of various derivatives in the current period, compared to - $1.7 million in losses for the same period in 2025.

#### Adjusted EBITDA

Adjusted EBITDA losses for Q1 2026 were - $5.804 million, compared to losses of - $5.537 million for Q1 2025. The increase in adjusted EBITDA losses was primarily driven by higher stock-based compensation and increased operating expenses.

#### Cash and Cash Equivalents

As of March 31, 2026, cash and cash equivalents totaled $56.553 million, a substantial increase from $20.439 million as of December 31, 2025.

#### Cash Flow from Operating Activities

Net cash used in operating activities for the three months ended March 31, 2026, was - $6.480 million, compared to - $4.499 million used in the same period of 2025.

#### Equity Funding

TriSalus Life Sciences completed a public offering during the quarter, raising $42.625 million in net proceeds from the issuance of common stock. The company believes these proceeds provide sufficient cash runway to fully fund commercial expansion and pipeline development.

#### Unique Operational Metrics

A landmark, real-world PEDD® Study of over 16,800 patients found that PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance, despite PEDD patients having greater baseline clinical complexity. New clinical and preclinical PEDD data were also presented across multiple oncology and embolization applications.

### Outlook / Guidance

TriSalus Life Sciences revised its 2026 revenue guidance to $54 million to $57 million, reflecting the impact of commercial expansion and the timing of FDA clearance for TriNav® Advance. The company believes the long-term growth opportunity for the PEDD platform remains substantial.

### Related Stocks

- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [Acteos delays H1 2026 results release to Oct. 28](https://longbridge.com/en/news/298618428.md)
- [Ecosuntek adds Q3 KPI update to 2026 corporate events calendar](https://longbridge.com/en/news/298712114.md)
- [Tractor Supply declares R$ 0.05 per-unit dividend for Q3 2026](https://longbridge.com/en/news/298615733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**